Lantern Pharma Inc. LTRN
1.22
0.01
0.83%
as of 25 Sep
- Market cap
- $15.5M
- P/E
- 0.0×
Follow LTRN
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
3.33 | 2.40 | 1.87 | 1.96 |
Net Debt/EBITDA |
2.74 | 2.40 | 1.86 | 2.10 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.09 | 0.69 | 1.13 | 0.42 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.42) | (0.26) | (0.34) | (0.24) | |
Cash per Share |
1.14 | 0.93 | 0.56 | 0.59 | |
Shareholders Equity per Share |
0.89 | 0.60 | 0.31 | (0.26) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.89 | 0.60 | 0.31 | (0.26) | |
Free Cash Flow |
(4.57) | (2.79) | (3.77) | (2.94) | |
Working Capital |
9.42 | 6.30 | 3.28 | 4.14 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
9.42 | 6.30 | 3.28 | (3.36) | |
| Other line items | |||||
Quick Ratio |
3.06 | 2.25 | 1.67 | 1.70 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.42) | (0.26) | (0.34) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.67 | 4.28 | 3.92 | 4.52 | |
Average Assets |
21.96 | 18.30 | 14.16 | 13.01 | |
Average Common Equity |
18.09 | 13.86 | 10.11 | 4.65 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates